We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
LeonaBio, Inc.는 임상 단계 바이오 제약 회사로, 치료 저항성 전이성 유방암 및 근위축성 측삭 경화증(ALS)과 같이 의학적 미충족 수요가 높은 질환을 위한 혁신적인 치료제 개발에 주력하고 있습니다. 이 회사의 주요 제품은 lasofoxifene과 ATH-1105로, 현재 치료법이 제한적이거나 효과적이지 않은 치명적인 질병을 해결할 잠재력을 가진 새로운 소분자 치료제입니다. 제품 파이프라인에는 1상 임상 시험 중인 근위축성 측삭 경화증 치료제 ATH-1105, 1상 임상 시험 중인 당뇨병성 신경병증 치료제 ATH-1020, 2상 임상 시험 중인 알츠하이머병 및 파킨슨병 치료제 ATH-1017이 있으며, 전임상 단계의 초기 화합물도 포함됩니다. 이 회사는 이전에 Athira Pharma, Inc.로 알려졌으며, 2026년 1월 LeonaBio, Inc.로 사명을 변경했습니다. LeonaBio, Inc.는 2011년에 설립되었으며, 워싱턴주 보셀에 본사를 두고 있습니다.